Search
Oportuzumab monatox
go.drugbank.com/drugs/DB05319InvestigationalVB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin
INKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
NM-702
go.drugbank.com/drugs/DB05505InvestigationalTherapeutic options to improve exercise performance in these patients are limited … It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment.
Asiatic acid
go.drugbank.com/drugs/DB14054InvestigationalFrom Centella asiatica and other plants; shows a variety of bioactivities.
Mixtures: Karatica Im Cica Essence PackMitoquinone
go.drugbank.com/drugs/DB05063InvestigationalMitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.
Synonyms: Mitoquinone ionForetinib
go.drugbank.com/drugs/DB12307InvestigationalForetinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. … Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others.
MRx-4DP0004
go.drugbank.com/drugs/DB15751InvestigationalMRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADETLigelizumab
go.drugbank.com/drugs/DB11856Investigationalefficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. … While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). … Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains.